FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:STARD10-CPT1A

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: STARD10-CPT1A
FusionPDB ID: 87148
FusionGDB2.0 ID: 87148
HgeneTgene
Gene symbol

STARD10

CPT1A

Gene ID

10809

1374

Gene nameStAR related lipid transfer domain containing 10carnitine palmitoyltransferase 1A
SynonymsCGI-52|NY-CO-28|PCTP2|SDCCAG28CPT1|CPT1-L|L-CPT1
Cytomap

11q13.4

11q13.3

Type of geneprotein-codingprotein-coding
DescriptionSTART domain-containing protein 10PCTP-LPCTP-like proteinSTART domain containing 10StAR-related lipid transfer (START) domain containing 10antigen NY-CO-28serologically defined colon cancer antigen 28stAR-related lipid transfer protein 10carnitine O-palmitoyltransferase 1, liver isoformCPT ICPTI-Lcarnitine O-palmitoyltransferase I, liver isoformcarnitine palmitoyltransferase 1A (liver)carnitine palmitoyltransferase I, liver
Modification date2020031320200315
UniProtAcc.

P50416

Main function of 5'-partner protein: FUNCTION: Catalyzes the transfer of the acyl group of long-chain fatty acid-CoA conjugates onto carnitine, an essential step for the mitochondrial uptake of long-chain fatty acids and their subsequent beta-oxidation in the mitochondrion (PubMed:9691089, PubMed:11350182, PubMed:14517221). Plays an important role in hepatic triglyceride metabolism (By similarity). {ECO:0000250|UniProtKB:P32198, ECO:0000269|PubMed:11350182, ECO:0000269|PubMed:14517221, ECO:0000269|PubMed:9691089}.
Ensembl transtripts involved in fusion geneENST idsENST00000334805, ENST00000543304, 
ENST00000538437, ENST00000538536, 
ENST00000545082, 
ENST00000537756, 
ENST00000538994, ENST00000265641, 
ENST00000376618, ENST00000539743, 
ENST00000540367, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score10 X 7 X 6=42012 X 9 X 8=864
# samples 1015
** MAII scorelog2(10/420*10)=-2.0703893278914
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(15/864*10)=-2.52606881166759
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: STARD10 [Title/Abstract] AND CPT1A [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: STARD10 [Title/Abstract] AND CPT1A [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)STARD10(72492019)-CPT1A(68562379), # samples:1
Anticipated loss of major functional domain due to fusion event.STARD10-CPT1A seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
STARD10-CPT1A seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
STARD10-CPT1A seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
STARD10-CPT1A seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
STARD10-CPT1A seems lost the major protein functional domain in Tgene partner, which is a cell metabolism gene due to the frame-shifted ORF.
STARD10-CPT1A seems lost the major protein functional domain in Tgene partner, which is a essential gene due to the frame-shifted ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
TgeneCPT1A

GO:0001676

long-chain fatty acid metabolic process

11350182

TgeneCPT1A

GO:0009437

carnitine metabolic process

11350182



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr11:72492019/chr11:68562379)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across STARD10 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across CPT1A (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000334805STARD10chr1172492019-ENST00000540367CPT1Achr1168562379-282311277762626616
ENST00000334805STARD10chr1172492019-ENST00000376618CPT1Achr1168562379-282111277762626616
ENST00000334805STARD10chr1172492019-ENST00000265641CPT1Achr1168562379-543311277762677633
ENST00000334805STARD10chr1172492019-ENST00000539743CPT1Achr1168562379-270911277762677633

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000334805ENST00000540367STARD10chr1172492019-CPT1Achr1168562379-0.0040285720.9959714
ENST00000334805ENST00000376618STARD10chr1172492019-CPT1Achr1168562379-0.0040967050.9959033
ENST00000334805ENST00000265641STARD10chr1172492019-CPT1Achr1168562379-0.0020479410.99795204
ENST00000334805ENST00000539743STARD10chr1172492019-CPT1Achr1168562379-0.0041786870.99582136

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for STARD10-CPT1A

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
STARD10chr1172492019CPT1Achr11685623791127117QAVEMDRTLHKIKDLLYILPTHIQAA

Top

Potential FusionNeoAntigen Information of STARD10-CPT1A in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
STARD10-CPT1A_72492019_68562379.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
STARD10-CPT1Achr1172492019chr11685623791127HLA-A30:08KIKDLLYIL0.98140.68151019
STARD10-CPT1Achr1172492019chr11685623791127HLA-A02:04KIKDLLYIL0.96360.53021019
STARD10-CPT1Achr1172492019chr11685623791127HLA-A02:21KIKDLLYIL0.95760.57771019
STARD10-CPT1Achr1172492019chr11685623791127HLA-A30:08RTLHKIKDL0.94810.6005615
STARD10-CPT1Achr1172492019chr11685623791127HLA-A32:13KIKDLLYIL0.94740.89641019
STARD10-CPT1Achr1172492019chr11685623791127HLA-B15:03LHKIKDLLY0.23330.536817
STARD10-CPT1Achr1172492019chr11685623791127HLA-B13:01TLHKIKDLL0.00840.9344716
STARD10-CPT1Achr1172492019chr11685623791127HLA-B57:01RTLHKIKDLLY0.9990.9399617
STARD10-CPT1Achr1172492019chr11685623791127HLA-B15:17RTLHKIKDLLY0.99230.8208617
STARD10-CPT1Achr1172492019chr11685623791127HLA-C15:06RTLHKIKDL0.99750.8771615
STARD10-CPT1Achr1172492019chr11685623791127HLA-B15:04KIKDLLYIL0.96940.80791019
STARD10-CPT1Achr1172492019chr11685623791127HLA-B15:07TLHKIKDLLY0.99040.6593717
STARD10-CPT1Achr1172492019chr11685623791127HLA-C15:02RTLHKIKDL0.99770.7799615
STARD10-CPT1Achr1172492019chr11685623791127HLA-A32:01KIKDLLYIL0.99130.90851019
STARD10-CPT1Achr1172492019chr11685623791127HLA-A30:01KIKDLLYIL0.9820.80291019
STARD10-CPT1Achr1172492019chr11685623791127HLA-A02:06KIKDLLYIL0.95760.57771019
STARD10-CPT1Achr1172492019chr11685623791127HLA-B15:73KIKDLLYIL0.94370.72871019
STARD10-CPT1Achr1172492019chr11685623791127HLA-B15:30KIKDLLYIL0.89890.67431019
STARD10-CPT1Achr1172492019chr11685623791127HLA-B15:54LHKIKDLLY0.04190.7864817
STARD10-CPT1Achr1172492019chr11685623791127HLA-B15:135TLHKIKDLLY0.99710.8721717
STARD10-CPT1Achr1172492019chr11685623791127HLA-B15:35TLHKIKDLLY0.98990.8762717
STARD10-CPT1Achr1172492019chr11685623791127HLA-B57:10RTLHKIKDLLY0.9990.9399617
STARD10-CPT1Achr1172492019chr11685623791127HLA-B57:04RTLHKIKDLLY0.99850.7115617
STARD10-CPT1Achr1172492019chr11685623791127HLA-B58:06RTLHKIKDLLY0.99610.6402617
STARD10-CPT1Achr1172492019chr11685623791127HLA-A32:01RTLHKIKDLLY0.95340.8881617

Top

Potential FusionNeoAntigen Information of STARD10-CPT1A in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
STARD10-CPT1A_72492019_68562379.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
STARD10-CPT1Achr1172492019chr11685623791127DRB1-0301QAVEMDRTLHKIKDL015
STARD10-CPT1Achr1172492019chr11685623791127DRB1-0303QAVEMDRTLHKIKDL015
STARD10-CPT1Achr1172492019chr11685623791127DRB1-0307QAVEMDRTLHKIKDL015
STARD10-CPT1Achr1172492019chr11685623791127DRB1-0313QAVEMDRTLHKIKDL015
STARD10-CPT1Achr1172492019chr11685623791127DRB1-0315QAVEMDRTLHKIKDL015
STARD10-CPT1Achr1172492019chr11685623791127DRB1-0318QAVEMDRTLHKIKDL015
STARD10-CPT1Achr1172492019chr11685623791127DRB1-0320QAVEMDRTLHKIKDL015
STARD10-CPT1Achr1172492019chr11685623791127DRB1-0322QAVEMDRTLHKIKDL015
STARD10-CPT1Achr1172492019chr11685623791127DRB1-0326QAVEMDRTLHKIKDL015
STARD10-CPT1Achr1172492019chr11685623791127DRB1-0328QAVEMDRTLHKIKDL015
STARD10-CPT1Achr1172492019chr11685623791127DRB1-0330QAVEMDRTLHKIKDL015
STARD10-CPT1Achr1172492019chr11685623791127DRB1-0332QAVEMDRTLHKIKDL015
STARD10-CPT1Achr1172492019chr11685623791127DRB1-0334QAVEMDRTLHKIKDL015
STARD10-CPT1Achr1172492019chr11685623791127DRB1-0336QAVEMDRTLHKIKDL015
STARD10-CPT1Achr1172492019chr11685623791127DRB1-0342QAVEMDRTLHKIKDL015
STARD10-CPT1Achr1172492019chr11685623791127DRB1-0344QAVEMDRTLHKIKDL015
STARD10-CPT1Achr1172492019chr11685623791127DRB1-0346QAVEMDRTLHKIKDL015
STARD10-CPT1Achr1172492019chr11685623791127DRB1-0348QAVEMDRTLHKIKDL015
STARD10-CPT1Achr1172492019chr11685623791127DRB1-0350QAVEMDRTLHKIKDL015
STARD10-CPT1Achr1172492019chr11685623791127DRB1-0352QAVEMDRTLHKIKDL015
STARD10-CPT1Achr1172492019chr11685623791127DRB1-0354QAVEMDRTLHKIKDL015
STARD10-CPT1Achr1172492019chr11685623791127DRB1-0415IKDLLYILPTHIQAA1126
STARD10-CPT1Achr1172492019chr11685623791127DRB1-0415KIKDLLYILPTHIQA1025
STARD10-CPT1Achr1172492019chr11685623791127DRB1-0436IKDLLYILPTHIQAA1126
STARD10-CPT1Achr1172492019chr11685623791127DRB1-0436KIKDLLYILPTHIQA1025
STARD10-CPT1Achr1172492019chr11685623791127DRB1-0437IKDLLYILPTHIQAA1126
STARD10-CPT1Achr1172492019chr11685623791127DRB1-0440IKDLLYILPTHIQAA1126
STARD10-CPT1Achr1172492019chr11685623791127DRB1-0442IKDLLYILPTHIQAA1126
STARD10-CPT1Achr1172492019chr11685623791127DRB1-0444IKDLLYILPTHIQAA1126
STARD10-CPT1Achr1172492019chr11685623791127DRB1-0453IKDLLYILPTHIQAA1126
STARD10-CPT1Achr1172492019chr11685623791127DRB1-0453KIKDLLYILPTHIQA1025
STARD10-CPT1Achr1172492019chr11685623791127DRB1-0456IKDLLYILPTHIQAA1126
STARD10-CPT1Achr1172492019chr11685623791127DRB1-0458IKDLLYILPTHIQAA1126
STARD10-CPT1Achr1172492019chr11685623791127DRB1-0468IKDLLYILPTHIQAA1126
STARD10-CPT1Achr1172492019chr11685623791127DRB1-0470IKDLLYILPTHIQAA1126
STARD10-CPT1Achr1172492019chr11685623791127DRB1-0473IKDLLYILPTHIQAA1126
STARD10-CPT1Achr1172492019chr11685623791127DRB1-1107QAVEMDRTLHKIKDL015
STARD10-CPT1Achr1172492019chr11685623791127DRB1-1201DRTLHKIKDLLYILP520
STARD10-CPT1Achr1172492019chr11685623791127DRB1-1201MDRTLHKIKDLLYIL419
STARD10-CPT1Achr1172492019chr11685623791127DRB1-1203DRTLHKIKDLLYILP520
STARD10-CPT1Achr1172492019chr11685623791127DRB1-1204IKDLLYILPTHIQAA1126
STARD10-CPT1Achr1172492019chr11685623791127DRB1-1205DRTLHKIKDLLYILP520
STARD10-CPT1Achr1172492019chr11685623791127DRB1-1205MDRTLHKIKDLLYIL419
STARD10-CPT1Achr1172492019chr11685623791127DRB1-1206DRTLHKIKDLLYILP520
STARD10-CPT1Achr1172492019chr11685623791127DRB1-1206MDRTLHKIKDLLYIL419
STARD10-CPT1Achr1172492019chr11685623791127DRB1-1207DRTLHKIKDLLYILP520
STARD10-CPT1Achr1172492019chr11685623791127DRB1-1207MDRTLHKIKDLLYIL419
STARD10-CPT1Achr1172492019chr11685623791127DRB1-1208DRTLHKIKDLLYILP520
STARD10-CPT1Achr1172492019chr11685623791127DRB1-1209IKDLLYILPTHIQAA1126
STARD10-CPT1Achr1172492019chr11685623791127DRB1-1210DRTLHKIKDLLYILP520
STARD10-CPT1Achr1172492019chr11685623791127DRB1-1210MDRTLHKIKDLLYIL419
STARD10-CPT1Achr1172492019chr11685623791127DRB1-1211DRTLHKIKDLLYILP520
STARD10-CPT1Achr1172492019chr11685623791127DRB1-1211MDRTLHKIKDLLYIL419
STARD10-CPT1Achr1172492019chr11685623791127DRB1-1212DRTLHKIKDLLYILP520
STARD10-CPT1Achr1172492019chr11685623791127DRB1-1212MDRTLHKIKDLLYIL419
STARD10-CPT1Achr1172492019chr11685623791127DRB1-1213DRTLHKIKDLLYILP520
STARD10-CPT1Achr1172492019chr11685623791127DRB1-1214DRTLHKIKDLLYILP520
STARD10-CPT1Achr1172492019chr11685623791127DRB1-1214MDRTLHKIKDLLYIL419
STARD10-CPT1Achr1172492019chr11685623791127DRB1-1215DRTLHKIKDLLYILP520
STARD10-CPT1Achr1172492019chr11685623791127DRB1-1217DRTLHKIKDLLYILP520
STARD10-CPT1Achr1172492019chr11685623791127DRB1-1217MDRTLHKIKDLLYIL419
STARD10-CPT1Achr1172492019chr11685623791127DRB1-1218DRTLHKIKDLLYILP520
STARD10-CPT1Achr1172492019chr11685623791127DRB1-1219DRTLHKIKDLLYILP520
STARD10-CPT1Achr1172492019chr11685623791127DRB1-1220DRTLHKIKDLLYILP520
STARD10-CPT1Achr1172492019chr11685623791127DRB1-1221DRTLHKIKDLLYILP520
STARD10-CPT1Achr1172492019chr11685623791127DRB1-1223DRTLHKIKDLLYILP520
STARD10-CPT1Achr1172492019chr11685623791127DRB1-1457IKDLLYILPTHIQAA1126

Top

Fusion breakpoint peptide structures of STARD10-CPT1A

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
8275RTLHKIKDLLYILPSTARD10CPT1Achr1172492019chr11685623791127

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of STARD10-CPT1A

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN8275RTLHKIKDLLYILP-7.15543-7.26883
HLA-B14:023BVN8275RTLHKIKDLLYILP-4.77435-5.80965
HLA-B52:013W398275RTLHKIKDLLYILP-6.80875-6.92215
HLA-B52:013W398275RTLHKIKDLLYILP-4.20386-5.23916
HLA-A11:014UQ28275RTLHKIKDLLYILP-7.5194-8.5547
HLA-A11:014UQ28275RTLHKIKDLLYILP-6.9601-7.0735
HLA-A24:025HGA8275RTLHKIKDLLYILP-7.52403-7.63743
HLA-A24:025HGA8275RTLHKIKDLLYILP-5.82433-6.85963
HLA-B27:056PYJ8275RTLHKIKDLLYILP-3.28285-4.31815
HLA-B44:053DX88275RTLHKIKDLLYILP-5.91172-6.94702
HLA-B44:053DX88275RTLHKIKDLLYILP-4.24346-4.35686

Top

Vaccine Design for the FusionNeoAntigens of STARD10-CPT1A

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
STARD10-CPT1Achr1172492019chr11685623791019KIKDLLYILAAGATCAAGGATCTGCTGTATATCCTT
STARD10-CPT1Achr1172492019chr1168562379615RTLHKIKDLCGGACGCTGCACAAGATCAAGGATCTG
STARD10-CPT1Achr1172492019chr1168562379617RTLHKIKDLLYCGGACGCTGCACAAGATCAAGGATCTGCTGTAT
STARD10-CPT1Achr1172492019chr1168562379716TLHKIKDLLACGCTGCACAAGATCAAGGATCTGCTG
STARD10-CPT1Achr1172492019chr1168562379717TLHKIKDLLYACGCTGCACAAGATCAAGGATCTGCTGTAT
STARD10-CPT1Achr1172492019chr1168562379817LHKIKDLLYCTGCACAAGATCAAGGATCTGCTGTAT

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
STARD10-CPT1Achr1172492019chr1168562379015QAVEMDRTLHKIKDLCAGGCTGTGGAGATGGATCGGACGCTGCACAAGATCAAGGATCTG
STARD10-CPT1Achr1172492019chr11685623791025KIKDLLYILPTHIQAAAGATCAAGGATCTGCTGTATATCCTTCCAACTCACATTCAGGCA
STARD10-CPT1Achr1172492019chr11685623791126IKDLLYILPTHIQAAATCAAGGATCTGCTGTATATCCTTCCAACTCACATTCAGGCAGCA
STARD10-CPT1Achr1172492019chr1168562379419MDRTLHKIKDLLYILATGGATCGGACGCTGCACAAGATCAAGGATCTGCTGTATATCCTT
STARD10-CPT1Achr1172492019chr1168562379520DRTLHKIKDLLYILPGATCGGACGCTGCACAAGATCAAGGATCTGCTGTATATCCTTCCA

Top

Information of the samples that have these potential fusion neoantigens of STARD10-CPT1A

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
STADSTARD10-CPT1Achr1172492019ENST00000334805chr1168562379ENST00000265641TCGA-BR-8362

Top

Potential target of CAR-T therapy development for STARD10-CPT1A

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to STARD10-CPT1A

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to STARD10-CPT1A

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource